🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

473 results for “Teva Pharma GmbH” Clear

  1. TAK-573

    Teva Pharma GmbH

    Relapsed and/or Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

  2. TEV-48125 - 1

    Teva Pharma GmbH

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  3. TEV-53408

    Teva Pharma GmbH

    Vitiligo

    phase 1 small molecule active

    1 trial

  4. TEV-56278

    Teva Pharma GmbH

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  5. TEV-56286

    Teva Pharma GmbH

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  6. TEV-56286 Test

    Teva Pharma GmbH

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  7. TL011

    Teva Pharma GmbH

    DLBCL

    phase 1 mab completed

    1 trial

  8. TL011, anti CD20, for the treatment of rheumatoid arthritis

    Teva Pharma GmbH

    Rheumatoid Arthritis

    phase 1 mab completed

    1 trial

  9. TV-45070

    Teva Pharma GmbH

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  10. TV-46046

    Teva Pharma GmbH

    Contraception

    phase 1 small molecule completed

    2 trials

  11. TV-46046 - 400 mg/mL

    Teva Pharma GmbH

    Pregnancy

    phase 1 small molecule completed

    1 trial

  12. TV46017

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease (COPD

    phase 1 small molecule terminated

    1 trial

  13. TV48108

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease

    phase 1 small molecule terminated

    1 trial

  14. Talampanel

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Talampanel (non-radiolabeled), [14C] Talampanel

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule terminated

    1 trial

  16. Tamsulosin

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  17. Terbinafine HCl 250mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  18. Topiramate 2 x 25 mg tablet

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  19. Topiramate 25 mg Capsules

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  20. Topiramate Capsules, 25 mg

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  21. Topiramate Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  22. Trandolapril 4 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  23. Treatment A: Fp MDPI

    Teva Pharma GmbH

    Asthma

    phase 1 small molecule completed

    1 trial

  24. Ursodiol

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources